In one study, incorporating 8 retrospective and prospective cohort studies and 1 case series, concluded that use of DPP-4 inhibitors was associated with 24% lower mortality in patients with COVID-19 (risk ratio 0.76, 95%-CI 0.60–0.97) [13]. Here, DPP4 is linked to COVID-19.